Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Phase 2 Study of RMC-4630 and Sotorasib for NSCLC patients with KRAS G12C mutation

A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Disease Types: Lung

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

For more information:

https://clinicaltrials.gov/ct2/show/NCT05054725?cond=Non-Small+Cell+Lung+Cancer+Subjects+with+KRAS+G12C+Mutation&draw=2&rank=3